There are 169 resources available
86O - Serial monitoring of circulating tumor DNA (ctDNA) as a tumor-agnostic biomarker to inform clinical outcomes of patients receiving experimental cancer medicine
Presenter: Kyrillus Shohdy
Session: Abstract session 2
Resources:
Abstract
Slides
Webcast
15O - Targeting CCNE1-amplified ovarian and endometrial cancers by combined inhibition of PKYMT1 and ATR
Presenter: Fiona Simpkins
Session: Abstract session 2
Resources:
Abstract
Slides
Webcast
1O - Uncovering new immunotherapy targets with machine learning and ex vivo validation
Presenter: Marcellus Augustine
Session: Abstract session 2
Resources:
Abstract
74O - Highly potent and selective RET inhibitors that overcome adaptive drug resistance
Presenter: Li Xing
Session: Abstract session 2
Resources:
Abstract
Slides
Webcast
28O - Comparison of prognostic scores in oncology patients participating in phase I clinical trials with immunotherapy
Presenter: PALOMA Sangro
Session: Abstract session 2
Resources:
Abstract
Slides
Webcast
29O - Clinical characterization of long-term survivors in phase I clinical trials
Presenter: Oriol Mirallas
Session: Abstract session 2
Resources:
Abstract
Slides
Webcast
6O - Subcutaneous fat mass predicts progression-free survival in patients treated with antibody drug conjugates in early phase clinical trials
Presenter: Matthieu Delaye
Session: Abstract session 2
Resources:
Abstract
Invited discussant abstracts 28O, 29O and 6O
Presenter: Louise Carter
Session: Abstract session 2
Resources:
Slides
Webcast
Q&A
Presenter: All Speakers
Session: Abstract session 2
Resources:
Webcast
Taking aim at the undruggable: Mutant-specific KRAS inhibitors, insights and perspectives
Presenter: Melissa Johnson
Session: Mutant specific inhibitors
Resources:
Slides
Webcast